DSDesy Fitrya Syamsumir

Desy Fitrya Syamsumir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Desy Fitrya Syamsumir has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of Potential Biomarkers and Metabolic Changes in the Serum of Breast Lump Patients Among Kelantanese Based on 1H NMR Metabolomics

    by Ahmad Zulkefly, Wan Norlina Wan Azman, Julia Omar, Nurul Syakima Ab Mutalib, Desy Fitrya Syamsumir, M Maulidiani, Faridah Abas, Maya Mazuwin Yahya, Muhamad Syahmi Yamin, Wan Faiziah Wan Abdul Rahman, et al.

    This case-control study, conducted at the Hospital USM BestARi unit, aimed to identify the serum metabolic fingerprint among individuals with breast lumps and healthy controls, and to discover potential biomarkers. Serum samples from healthy controls, benign breast lump patients, and malignant breast lump patients were analyzed using proton nuclear magnetic resonance spectroscopy (1H NMR). A multivariate data analysis approach was employed, with the OPLS-DA and clustered heat map techniques effectively differentiating between the three groups. The study revealed significant metabolite variations across the groups and proposed D-glucose, glycerol, and glycine as potential biomarkers for breast cancer diagnosis. Metabolic pathways such as alanine, aspartate, glutamate metabolism, and glycine, serine, and threonine metabolism were implicated. The metabolomics approach coupled with multivariate analysis successfully identified key metabolites leading to group separation and suggested altered metabolic pathways. However, further research and integration with other ‘omics’ technologies are necessary for clinical translation.


  • Open Access

    Inhibitory effects of tangeretin and trans-ethyl caffeate on the HMG-CoA reductase activity: Potential agents for reducing cholesterol levels

    by Inten Pangestika, Efriyana Oksal, Tengku Sifzizul Tengku Muhammad, Hermansyah Amir, Desy Fitrya Syamsumir, Mohd Effendy Abdul Wahid, Yosie Andriani


  • Open Access

    Phaleria macrocarpa Boerl. (Thymelaeaceae) Leaves Increase SR-BI Expression and Reduce Cholesterol Levels in Rats Fed a High Cholesterol Diet

    by Yosie Andriani, Tengku Sifzizul Tengku-Muhammad, Habsah Mohamad, Jasnizat Saidin, Desy Fitrya Syamsumir, Guat-Siew Chew, Mohd Effendy Abdul Wahid

    In vitro and in vivo studies of the activity of Phaleria macrocarpa Boerl (Thymelaeaceae) leaves against the therapeutic target for hypercholesterolemia were done using the HDL receptor (SR-BI) and hypercholesterolemia-induced Sprague Dawley rats. The in vitro study showed that the active fraction (CF6) obtained from the ethyl acetate extract (EMD) and its component 2',6',4-trihydroxy-4'-methoxybenzophenone increased the SR-BI expression by 95% and 60%, respectively. The in vivo study has proven the effect of EMD at 0.5 g/kgbw dosage in reducing the total cholesterol level by 224.9% and increasing the HDL cholesterol level by 157% compared to the cholesterol group. In the toxicity study, serum glutamate oxalate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) activity were observed to be at normal levels. The liver histology also proved no toxicity and abnormalities in any of the treatment groups, so it can be categorized as non-toxic to the rat liver. The findings taken together show that P. macrocarpa leaves are safe and suitable as an alternative control and prevention treatment for hypercholesterolemia in Sprague Dawley rats.